Boston Scientific Net Profit Margin 2010-2025 | BSX
Current and historical net profit margin for Boston Scientific (BSX) from 2010 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue. Boston Scientific net profit margin for the three months ending March 31, 2025 was .
| Boston Scientific Net Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Net Income | Net Margin |
| 2025-03-31 | $17.55B | $2.03B | 11.58% |
| 2024-12-31 | $16.75B | $1.85B | 11.06% |
| 2024-09-30 | $15.91B | $1.79B | 11.26% |
| 2024-06-30 | $15.23B | $1.83B | 12.00% |
| 2024-03-31 | $14.71B | $1.77B | 12.00% |
| 2023-12-31 | $14.24B | $1.57B | 11.03% |
| 2023-09-30 | $13.76B | $1.19B | 8.66% |
| 2023-06-30 | $13.40B | $0.86B | 6.42% |
| 2023-03-31 | $13.05B | $0.85B | 6.48% |
| 2022-12-31 | $12.68B | $0.64B | 5.06% |
| 2022-09-30 | $12.57B | $0.60B | 4.76% |
| 2022-06-30 | $12.33B | $0.83B | 6.72% |
| 2022-03-31 | $12.16B | $0.76B | 6.21% |
| 2021-12-31 | $11.89B | $0.99B | 8.29% |
| 2021-09-30 | $11.47B | $1.10B | 9.59% |
| 2021-06-30 | $11.20B | $0.53B | 4.70% |
| 2021-03-31 | $10.12B | $0.20B | 1.99% |
| 2020-12-31 | $9.91B | $-0.12B | -1.16% |
| 2020-09-30 | $10.11B | $3.69B | 36.45% |
| 2020-06-30 | $10.16B | $3.98B | 39.18% |
| 2020-03-31 | $10.79B | $4.29B | 39.75% |
| 2019-12-31 | $10.74B | $4.70B | 43.78% |
| 2019-09-30 | $10.39B | $1.09B | 10.49% |
| 2019-06-30 | $10.08B | $1.40B | 13.85% |
| 2019-03-31 | $9.94B | $1.80B | 18.08% |
| 2018-12-31 | $9.82B | $1.67B | 17.01% |
| 2018-09-30 | $9.67B | $0.67B | 6.93% |
| 2018-06-30 | $9.50B | $0.52B | 5.48% |
| 2018-03-31 | $9.27B | $0.11B | 1.21% |
| 2017-12-31 | $9.05B | $0.10B | 1.15% |
| 2017-09-30 | $8.83B | $0.84B | 9.55% |
| 2017-06-30 | $8.71B | $0.79B | 9.04% |
| 2017-03-31 | $8.58B | $0.44B | 5.07% |
| 2016-12-31 | $8.39B | $0.35B | 4.14% |
| 2016-09-30 | $8.17B | $0.08B | 0.99% |
| 2016-06-30 | $7.96B | $-0.35B | -4.34% |
| 2016-03-31 | $7.67B | $-0.04B | -0.47% |
| 2015-12-31 | $7.48B | $-0.24B | -3.20% |
| 2015-09-30 | $7.39B | $-0.40B | -5.36% |
| 2015-06-30 | $7.34B | $-0.16B | -2.11% |
| 2015-03-31 | $7.37B | $-0.25B | -3.43% |
| 2014-12-31 | $7.38B | $-0.12B | -1.61% |
| 2014-09-30 | $7.33B | $0.29B | 3.93% |
| 2014-06-30 | $7.22B | $0.24B | 3.32% |
| 2014-03-31 | $7.16B | $0.37B | 5.11% |
| 2013-12-31 | $7.14B | $-0.12B | -1.69% |
| 2013-09-30 | $7.13B | $-0.17B | -2.36% |
| 2013-06-30 | $7.13B | $-0.83B | -11.61% |
| 2013-03-31 | $7.14B | $-4.54B | -63.48% |
| 2012-12-31 | $7.25B | $-4.07B | -56.12% |
| 2012-09-30 | $7.28B | $-4.02B | -55.27% |
| 2012-06-30 | $7.42B | $-3.22B | -43.37% |
| 2012-03-31 | $7.56B | $0.51B | 6.72% |
| 2011-12-31 | $7.62B | $0.44B | 5.79% |
| 2011-09-30 | $7.78B | $0.57B | 7.33% |
| 2011-06-30 | $7.82B | $0.62B | 7.90% |
| 2011-03-31 | $7.77B | $0.57B | 7.33% |
| 2010-12-31 | $7.81B | $-1.07B | -13.64% |
| 2010-09-30 | $7.88B | $-2.38B | -30.15% |
| 2010-06-30 | $7.99B | $-2.66B | -33.30% |
| 2010-03-31 | $8.14B | $-2.60B | -31.96% |
| 2009-12-31 | $8.19B | $-1.03B | -12.52% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $153.655B | $16.747B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $232.442B | 27.95 |
| Stryker (SYK) | United States | $150.679B | 31.51 |
| EssilorLuxottica (ESLOY) | France | $135.238B | 0.00 |
| Medtronic (MDT) | Ireland | $114.659B | 16.25 |
| Lonza Group Ag (LZAGY) | Switzerland | $51.418B | 0.00 |
| Haleon (HLN) | United Kingdom | $45.416B | 25.92 |
| ResMed (RMD) | United States | $37.840B | 28.42 |
| Agilent Technologies (A) | United States | $35.272B | 22.99 |
| GE HealthCare Technologies (GEHC) | United States | $35.028B | 16.63 |
| Terumo (TRUMY) | Japan | $24.711B | 32.10 |
| Koninklijke Philips (PHG) | Netherlands | $23.746B | 16.66 |
| Insulet (PODD) | United States | $20.930B | 82.15 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.825B | 12.09 |
| Baxter (BAX) | United States | $15.241B | 11.38 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.608B | 0.00 |
| Demant (WILYY) | Denmark | $8.971B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.561B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.072B | 24.61 |
| Lantheus Holdings (LNTH) | United States | $5.800B | 14.63 |
| Prestige Consumer Healthcare (PBH) | United States | $3.832B | 17.12 |
| Haemonetics (HAE) | United States | $3.755B | 17.10 |
| Perrigo (PRGO) | Ireland | $3.749B | 9.50 |
| Envista Holdings (NVST) | United States | $3.512B | 29.18 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| ICU Medical (ICUI) | United States | $3.378B | 24.91 |
| QuidelOrtho (QDEL) | United States | $2.134B | 14.67 |
| LeMaitre Vascular (LMAT) | United States | $1.937B | 43.31 |
| AtriCure (ATRC) | United States | $1.587B | 0.00 |
| Acuren (TIC) | United States | $1.427B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.357B | 30.52 |
| AdaptHealth (AHCO) | United States | $1.275B | 12.94 |
| Phibro Animal Health (PAHC) | United States | $1.262B | 16.14 |
| Neogen (NEOG) | United States | $1.211B | 15.50 |
| BioLife Solutions (BLFS) | United States | $1.087B | 0.00 |
| InMode (INMD) | Israel | $0.960B | 9.67 |
| Curaleaf Holdings (CURLF) | Canada | $0.818B | 0.00 |
| Kestra Medical Technologies (KMTS) | United States | $0.780B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.736B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.641B | 0.00 |
| Owens & Minor (OMI) | United States | $0.640B | 5.31 |
| Evolus (EOLS) | United States | $0.627B | 0.00 |
| CeriBell (CBLL) | United States | $0.606B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.521B | 0.00 |
| Valneva SE (VALN) | France | $0.511B | 0.00 |
| Surmodics (SRDX) | United States | $0.444B | 0.00 |
| SNDL (SNDL) | Canada | $0.373B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.352B | 12.94 |
| Cresco Labs (CRLBF) | United States | $0.342B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.307B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.304B | 0.00 |
| Cerus (CERS) | United States | $0.296B | 0.00 |
| Quanterix (QTRX) | United States | $0.292B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.276B | 23.27 |
| Sanara MedTech (SMTI) | United States | $0.273B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.264B | 78.17 |
| ZimVie (ZIMV) | United States | $0.262B | 11.90 |
| Brainsway (BWAY) | Israel | $0.239B | 63.17 |
| Biote (BTMD) | United States | $0.230B | 6.48 |
| OraSure Technologies (OSUR) | United States | $0.228B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.225B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.219B | 0.00 |
| Omeros (OMER) | United States | $0.203B | 0.00 |
| Organigram Global (OGI) | Canada | $0.197B | 0.00 |
| High Tide (HITI) | Canada | $0.194B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.189B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.186B | 15.14 |
| Vireo Growth (VREOF) | United States | $0.164B | 0.00 |
| Exagen (XGN) | United States | $0.149B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.124B | 15.25 |
| TerrAscend (TSNDF) | Canada | $0.115B | 0.00 |
| Fonar (FONR) | United States | $0.100B | 12.91 |
| MacroGenics (MGNX) | United States | $0.100B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.098B | 0.00 |
| Jin Medical (ZJYL) | China | $0.095B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.087B | 0.00 |
| Veru (VERU) | United States | $0.085B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.083B | 0.00 |
| Apyx Medical (APYX) | United States | $0.082B | 0.00 |
| InterCure (INCR) | Israel | $0.073B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.071B | 0.00 |
| Agape ATP (ATPC) | $0.071B | 0.00 | |
| Zynex (ZYXI) | United States | $0.070B | 0.00 |
| ImmuCell (ICCC) | United States | $0.059B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.044B | 0.00 |
| Modular Medical (MODD) | United States | $0.041B | 0.00 |
| Nephros (NEPH) | United States | $0.040B | 53.57 |
| United-Guardian (UG) | United States | $0.038B | 13.02 |
| Safety Shot (SHOT) | United States | $0.032B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.022B | 0.00 |
| Flora Growth (FLGC) | United States | $0.016B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.015B | 0.00 |
| INLIF (INLF) | $0.015B | 0.00 | |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.014B | 0.00 |
| Senestech (SNES) | United States | $0.012B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Sharps Technology (STSS) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |